Vallejo M S, Witis S, Ojeda E, Mostajo D, Morera F, Meruvia N, Martino M, Lima S, Espinoza M T, Castillo O, Campostrini B, Danckers L, Blümel J E, Tserotas K, Sánchez H, Salinas C, Saavedra J, Rojas J A, Onatra W, Monterrosa A, Montaño A, Martínez J, González E, Gómez G, Calle A, Broutin G, Bencosme A, Arteaga E, Ayala F, Chedraui P
a Collaborative Group for Research of the Climacteric in Latin America (REDLINC) ;
b Departamento de Medicina Interna Sur, Facultad de Medicina , Universidad de Chile , Santiago de Chile , Chile ;
Climacteric. 2016 Aug;19(4):387-92. doi: 10.1080/13697137.2016.1191460. Epub 2016 Jun 21.
To evaluate whether menopausal status and symptoms among female gynecologists would influence their clinical behavior related to menopausal hormone therapy (MHT).
Female gynecologists of 11 Latin American countries were requested to fill out the Menopause Rating Scale and a questionnaire containing personal information and that related to MHT use.
A total of 818 gynecologists accepted to participate (86.4%). Overall, the mean age was 45.0 ± 10.7 years, 32.2% were postmenopausal, and 17.6% worked in an academic position; 81.8% reported that they would use MHT if they have symptoms, regardless of menopausal status. Academic gynecologists favor personal MHT use at a higher rate (p = 0.04) and have a higher MHT prescription rate as compared to non-academic ones (p = 0.0001). The same trend was observed among post- as compared to premenopausal ones (p = 0.01) and among those who had hysterectomy alone as compared to those experiencing natural menopause (p = 0.002). The presence of menopausal symptoms did not influence their MHT prescription. Current use of MHT and alternative therapy was higher among post- than premenopausal gynecologists (both, p = 0.0001) and among those who had undergone hysterectomy than those experiencing natural menopause. A 38.5% perceived breast cancer as the main risk related to MHT, and a high proportion prescribed non-hormonal drugs (86.4%) or alternative therapies (84.5%).
Most female gynecologists in this survey would use MHT if menopausal symptoms were present. Postmenopausal physicians use MHT and prescribe it to their symptomatic patients at a higher rate than premenopausal physicians.
评估女性妇科医生的绝经状态和症状是否会影响她们与绝经激素治疗（MHT）相关的临床行为。
邀请11个拉丁美洲国家的女性妇科医生填写绝经评定量表以及一份包含个人信息和与MHT使用相关信息的问卷。
共有818名妇科医生同意参与（86.4%）。总体而言，平均年龄为45.0±10.7岁，32.2%已绝经，17.6%从事学术工作；81.8%报告称如果出现症状，无论绝经状态如何，她们都会使用MHT。与非学术妇科医生相比，学术妇科医生更倾向于个人使用MHT（p = 0.04），且MHT处方率更高（p = 0.0001）。绝经后妇科医生与绝经前妇科医生相比（p = 0.01），以及单纯子宫切除的医生与自然绝经的医生相比（p = 0.002），也观察到了相同的趋势。绝经症状的存在并未影响她们的MHT处方。绝经后妇科医生中MHT和替代疗法的当前使用率高于绝经前妇科医生（均为p = 0.0001），且接受子宫切除的医生高于自然绝经的医生。38.5%认为乳腺癌是与MHT相关的主要风险，并且很大一部分人开具非激素类药物（86.4%）或替代疗法（84.5%）。
本次调查中的大多数女性妇科医生如果出现绝经症状会使用MHT。绝经后医生使用MHT并将其开给有症状患者的比例高于绝经前医生。
